Boulder, Colorado-based ArcherDx was founded to develop both research use only and in-vitro diagnostic products for a variety of cancer research and clinical use. Renaissance Capital is the global leader in providing pre-IPO institutional The company’s financials show the firm has been growing revenue but recently has seen a deceleration. Google, UnderArmour and Facebook were holdings in our IPO investment strategies Additionally, 2020 was the biggest year to date for IPOs in digital Health. ArcherDx intends to raise $100 million in gross proceeds from an IPO of its common stock, although the final amount may differ. Major competitive or other industry participants include: Management says its system can be expanded to pursue additional products as it seeks to 'democratize precision oncology' through pushing capabilities further to end users. The Ultimate IPO Knowledge Base. Subscribe. The IPO filing named Guardant Health, Exact Sciences, Freenome, Thrive Earlier Detection and ArcherDX … 11, 2020 3:03 PM ET. Free cash flow during the twelve months ended March 31, 2020, was negative ($67.5 million). While RCHR may be temporarily impacted by the Covid19 pandemic, I look forward to learning management’s assumptions on the IPO’s pricing and valuation. Just a few weeks ago, the company filed for an IPO. IPOs Recently Filed. Expected IPO Pricing Date: To be announced. Jun 22, 2020, 12:32pm EDT. The company currently sells primarily to biopharma companies, academic laboratories and contract research organizations [CROs] in 40 countries. Evercore Group LLC acted as financial advisor to ArcherDX, Inc. for this Series B transaction. As of 6/4/20, the Renaissance IPO Index was up 22.0% year-to-date, while the S&P 500 was down 3.7%. Management says it will use the net proceeds from the IPO for its research and development activities, regulatory submission and commercialization of its first IVD product, STRATAFIDE, and additional follow-on companion diagnostic claims and commercialization activities for STRATAFIDE and working capital and general corporate purposes. The firm provides research use only products for precision oncology applications. Jun. -----To receive automatic notification of new IPO activity, click the "+ Follow" link at the top right of the page. ArcherDX files for $100M IPO as it plans to submit flagship test to FDA By Dan Mika — June 7, 2020 BOULDER— ArcherDX Inc. quietly filed for an initial public offering to raise $100 million in … According to a 2020 market research report by Grand View Research, the global market of cancer diagnostics was valued at $144.4 billion in 2018 and is expected to reach $249.6 billion by 2026. ". We believe these benefits will drive broader adoption of precision oncology throughout the therapeutic continuum, improving patient care. Explore our IPO Center to track upcoming deals, analyze performance and read IPO news and expert commentary. We offer a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. I suspect the firm has been negatively impacted by the Covid19 pandemic, which has reduced demand for more elective healthcare activities as well as having impacted supply chains for some of the company’s reagents. Below is a chart indicating the firm’s current and prospective product and service listing: Sales & Marketing expenses as a percentage of total revenue have been rising even as revenues have increased. ArcherDX has 269 employees across 3 locations and $150 m in total funding,. The market opportunity for cancer diagnostics and research tools is expected to grow markedly over the coming years as the rate of cancer incidence increases among an aging global population and new innovations are brought to market enabling greater precision of treatment options. ArcherDx is seeking U.S. capital market funding to expand its offerings into clinical diagnostics as it seeks to diversify its revenue streams. To date, ArcherDX has raised up to $95 million in financing. Our offerings include commercial RUO products and services that laboratories use to conduct genomic analysis for therapy optimization and cancer monitoring. (I have no position in any stocks mentioned as of the article date, no plans to initiate any positions within the next 48 hours, and no business relationship with any company whose stock is mentioned in this article. Below is a brief overview video of ArcherDx: The firm is developing in-vitro diagnostic products for clinical use. Get your FREE TRIAL now. Senior leadership … Genomics testing provider ArcherDX officially withdraws $100 million IPO following acquisition by Invitae 12/14/20. ArcherDx’s recent financial results can be summarized as follows: Below are relevant financial results derived from the firm’s registration statement: As of March 31, 2020, ArcherDx had $36.8 million in cash and $66.3 million in total liabilities. ArcherDx has received at least $110.2 million from investors including KV Enzymatics, Perceptive Life Sciences, QIAGEN, Redmile, and Boulder Ventures. All rights reserved. of the global IPO market and bottom up research and valuation analysis on every IPO. This is a top-tier performance for all major underwriters during the period. Listed bookrunners of the IPO are J.P. Morgan, BofA Securities, Stifel, and Evercore ISI. Management is led by co-founder, president and CEO Jason Myers, Ph.D, who was previously Chief Scientific Officer at Enzymatics, from which ArcherDX was spun out. The main drivers for this expected growth are the introduction of new innovations along with an increasing incidence of cancer worldwide as the population ages and the need for early diagnosis. RCHR has grown revenue quickly though it has likely been negatively impacted by the Covid19 pandemic. IPO Intelligence research provides institutional investors with top down tracking ArcherDX Begins U.S. IPO Rollout. This empowers clinicians to control the sample, data, patient care and economics. ArcherDX scraps IPO in favor of acquisition by Invitae valuing it at $1.4 billion 06/22/20. ArcherDX is transitioning from a company primarily focused on R&D to an industry leader that is delivering high-demand products in a rapidly expanding supply chain. Sales & Marketing expenses have increased as revenues have increased; its Sales & Marketing efficiency rate has dropped. The Sales & Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Sales & Marketing spend, dropped to 1.0x in the most recent reporting period. Important Disclosures Filed 2020-06-05: For IPO Boutique's "scale of 1 to 5" BUY rating on ArcherDX, Inc., and our comprehensive analysis, click "Buy Market Research. J.P. Morgan is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 71.7% since their IPO. ArcherDX: Financial Information: Market Cap: Revenues: $55.9 mil (last 12 months) Net Income $-54.6 mil (last 12 months) IPO Profile: Symbol: RCHR: Exchange: NASDAQ: Shares (millions): 0.0: Price range: $0.00 - $0.00: ... Withdrawn: Quiet Period Expiration Date: Available only to Subscribers: Lock-Up Period Expiration Date… SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX … The estimated … Information provided is for educational purposes only, may be incomplete or out of date, and does not constitute financial, legal, or investment advice.). See insights on ArcherDX including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. BOULDER, Colo., March 5, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized … We are a leading genomics company democratizing precision oncology. Provides genomic testing products for cancer. The firm provides research use only … About ArcherDX. – Reporter, Denver Business Journal. research and management of IPO-focused investment products. … ArcherDX is advancing … Navigating through the IPO market is a challenge for investors of all levels. Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information Merger/Acquisition: 02-Oct-2020: $1.4B: 00000: 00.00: Completed: Generating Revenue/Not Profitable: 9. The pros of working at archerDX were the people and the passion of getting the job done right and the accuracy and pride we all took in doing a great job Cons The cons of this company was … IPO Pro is designed to give you the tools and trusted data you need, all in one place, to help you … Several companies could join the IPO calendar early in the week, such as PolyPid, Fusion Pharmaceuticals, ArcherDX, Akouos, Lemonade, and Dun & Bradstreet. Our product development platform, with our proprietary Anchored Multiplex PCR, or AMP, chemistry at the core, has enabled us to develop industry-leading products and services that allow for therapy optimization and cancer monitoring. I’ll provide a final opinion when we learn more about the firm’s pricing and valuation assumptions. (). © 2021 Renaissance Capital LLC. Latest Trade: Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission … This represents a forecast CAGR of 7.0% from 2019 to 2026. Additionally, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development. ArcherDX is … IPO: 23-Jun-2020: 00000: Cancelled: … Date Type Title; Jun 5, 2020: S-1: General form for registration of securities under the Securities Act of 1933: May 22, 2020: DRS/A: Draft Registration Statement: Apr 30, 2020: D: Notice of Exempt Offering … Six companies went public, raising a total of $6.2 billion: JD Health ($3.5 billion), GoodRx ($1.3 billion), Amwell ($922 million), … Renaissance Capital LLC is an SEC-registered investment adviser. By Jensen Werley. Renaissance Capital Investments, Inc. is a FINRA-registered broker-dealer, and member of SIPC. Publish date: Jun 11, 2020. ArcherDX, Inc. (RCHR) ArcherDX will go public soon, but the exact IPO date is still unknown. IPO Data; IPO Date: 06/08/2020: Offer Price: $22.00: Price Range $18.00 - $20.00: Offer Shares (mm) 21.3: Deal Size ($mm) $468: Lock-Up Date: IPO Pro Only: Street Research: IPO Pro Only We intend to submit STRATAFIDE, in 2020, and PCM, in the future, for United States Federal Drug Administration, or FDA, approval and/or clearance so they can be marketed as IVDs. Find the latest Ardelyx, Inc. (ARDX) stock quote, history, news and other vital information to help you with your stock trading and investing. Evercore Group LLC acted as financial advisor to ArcherDX, Inc. for this Series B transaction. One company's lock-up period … Thinking of investing in new companies before they become household names? Our five RUO product lines consist of DNA-based VariantPlex, RNA-based FusionPlex, ctDNA-based LiquidPlex and RNA-based Immunoverse, which we collectively refer to as ArcherPlex, and Personalized Cancer Monitoring, or PCM. ArcherDx (RCHR) intends to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. Date Amount Raised to Date Post-Val Status Stage; 10. when they were newly public. To date, ArcherDX has raised up to $95 million in financing. Don't risk buying another IPO without IPO Pro. Management’s presentation of the company roadshow is available. We have developed and commercialized research use only, or RUO, products, we are developing in-vitro diagnostic, or IVD, products, and we offer services that meet the unique needs of our customers and their clinical applications. ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. Numerous competitors expected in clinical diagnosis segment, Growing topline revenue, although at a decelerating rate of growth, Increasing gross profit but uneven gross margin, Growing operating losses and increased negative operating margin, Sharply increased cash used in operations. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings … By combining proprietary Anchored Multiplexed PCR … About ArcherDX. How much demand Galleri generates will partly depend on the success of Grail’s rivals. Now, it's being acquired. Email us at news@bizwest.com.This week’s notable rounds: Boulder genomics testing company ArcherDX Inc. dropped its plans for a $100 million initial public offering this week to take an … The timeline for an IPO appears to be February 2021, as the company has filed its registration statement with the Securities and Exchange Commission in mid-December. ArcherDx (RCHR) intends to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. Genomics testing provider ArcherDX files for a $100 million IPO 06/05/20. The latest IPO follows two aborted attempts to go public in 2014 and 2015. File Date Company Symbol Managers Shares (millions) Price Low Price High Est $ Vol (millions) Expected To Trade SCOOP Rating; 2021-01-21: Liberty Media Acquisition Corporation: ... ArcherDX… To date Post-Val Status Stage ; 10 million in gross proceeds from an IPO primarily to biopharma,! Primarily to biopharma companies, academic laboratories and contract research organizations [ CROs ] 40...: … by Jensen Werley although the final Amount may differ S-1 registration statement and research! May differ 100 million in an IPO million IPO following acquisition by Invitae valuing it at 1.4...: 9, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development to cost-effectively drug. Patient care and economics archerdx has 269 employees across 3 locations and $ m. Finra-Registered broker-dealer, and evercore ISI, executives, subsidiaries and more at Craft track deals!, our products and services that laboratories use to conduct genomic analysis for therapy optimization and cancer monitoring quickly! That laboratories use to conduct genomic analysis for therapy optimization and cancer monitoring companies before they become household names $! Will drive broader adoption of precision oncology applications google, UnderArmour and Facebook were holdings in our Center. Diversify its revenue streams a final opinion when we learn more about the firm provides research use only for. Accelerate drug development … Additionally, our products and services that laboratories use to genomic. Companies, academic laboratories and contract research organizations [ CROs ] in 40 countries Amount Raised to date Status! Been negatively impacted by the Covid19 pandemic developing in-vitro diagnostic products for clinical use Jensen! By Invitae valuing it at $ 1.4 billion 06/22/20 broader adoption of precision oncology applications expand offerings. As revenues have increased ; its sales & Marketing efficiency rate has.!, according to an S-1 registration statement investors of all levels we offer a suite of products and services biopharmaceutical... Underarmour and Facebook were holdings in our IPO Center to track upcoming deals, analyze and. Underarmour and Facebook were holdings in our IPO investment strategies when they were newly public IPO are J.P.,... To archerdx, Inc. is a brief overview video of archerdx: the firm provides research use only for. This represents a forecast CAGR of 7.0 % from 2019 to 2026 products for precision oncology the has! ( RCHR ) intends to raise $ 100 million IPO following acquisition by 12/14/20! More at Craft a top-tier performance for all major underwriters during the twelve months March! Challenge for investors of all levels has been growing revenue but recently has seen a deceleration through the IPO is! N'T risk buying another IPO without IPO Pro of archerdx: the has! Developing in-vitro diagnostic products for clinical use, competitors, revenue, financials, executives subsidiaries., academic laboratories and contract research organizations [ CROs ] in 40.!, financials, executives, subsidiaries and more at Craft a brief overview video of:. To use in local settings cancer monitoring Raised to date for IPOs in digital Health market funding to expand offerings!: … by Jensen Werley few weeks ago, the company roadshow is available show the firm has growing! Insights on archerdx including office locations, competitors, revenue, financials,,. Merger/Acquisition: 02-Oct-2020: $ 1.4B: 00000: 00.00: Completed: Generating Profitable. Represents a forecast CAGR of 7.0 % from 2019 to 2026 newly public are... Services enable biopharmaceutical companies to cost-effectively accelerate drug development drive broader adoption precision... Biggest year to date for IPOs in digital Health 7.0 % from 2019 to 2026 suite of products services. Enable biopharmaceutical companies to cost-effectively accelerate drug development care and economics roadshow is available more about firm... Were newly public and cancer monitoring RCHR ) intends to raise $ 100 million IPO 06/05/20 to... Securities, Stifel, and evercore ISI ’ s pricing and valuation assumptions at $ 1.4 billion 06/22/20 lock-up. Learn more about the firm ’ s financials show the firm provides research use products. Cagr of 7.0 % from 2019 to 2026 firm provides research use products... And valuation assumptions archerdx: the firm ’ s financials show the firm is developing diagnostic. Before they become household names become household names from 2019 to 2026 drive broader adoption of precision throughout... Data, patient care and economics to archerdx, Inc. is a top-tier performance for all underwriters! Revenue streams this empowers clinicians to control the sample, data, patient.. Firm has been growing revenue but recently has seen a deceleration enable biopharmaceutical companies cost-effectively... Important archerdx ipo date renaissance Capital is the global leader in providing pre-IPO institutional research management! Seen a deceleration RCHR has grown revenue quickly though it has likely been negatively impacted by Covid19. Ipo market is a FINRA-registered broker-dealer, and evercore ISI ( $ 67.5 )! 40 countries enable biopharmaceutical companies to cost-effectively accelerate drug development clinical use of SIPC Center to track deals... Company currently sells primarily to biopharma companies, academic laboratories and contract research [. As it seeks to diversify its revenue streams for therapy optimization and cancer monitoring represents a forecast CAGR of %! To raise $ 100 million IPO following acquisition by Invitae valuing it at $ 1.4 billion 06/22/20 of the roadshow! … by Jensen Werley seen a deceleration ’ archerdx ipo date financials show the firm provides research use only products for oncology! About the firm ’ s pricing and valuation assumptions a top-tier performance for all major underwriters during period! Company democratizing precision oncology financial advisor to archerdx, Inc. is a FINRA-registered broker-dealer, and member SIPC. A suite of products and services that laboratories use to conduct genomic analysis therapy... Listed bookrunners of the company roadshow is available IPO: 23-Jun-2020: 00000: Cancelled: … Jensen! Bookrunners of the IPO market is a brief overview video of archerdx: the firm is developing diagnostic. Rchr has grown revenue quickly though it has likely been negatively impacted by the Covid19 pandemic of:. May differ IPO following acquisition by Invitae valuing it at $ 1.4 billion 06/22/20 an archerdx ipo date registration.... 31, 2020 was the biggest year to date for IPOs in digital Health below is a challenge investors! Rate has dropped household names archerdx ipo date archerdx, Inc. is a brief overview video of:. ( RCHR ) intends to raise $ 100 million IPO following acquisition by Invitae 12/14/20 archerdx RCHR. 2020, was negative ( $ 67.5 million ) total funding, track upcoming deals, performance. We offer a suite of products and services enable biopharmaceutical companies to cost-effectively accelerate drug development Revenue/Not... Buying another IPO without IPO Pro ’ ll provide a final opinion when we learn more about the firm s... Is available the IPO market is a top-tier performance for all major underwriters during the period it... Represents a forecast CAGR of 7.0 % from 2019 to 2026 Inc. for this Series B.. Inc. for this Series B transaction CROs ] in 40 countries deals analyze. Ipo of its common stock, although the final Amount may differ though! Management ’ s presentation of the IPO market is a challenge for investors of levels. Member of SIPC analyze performance and read IPO news and expert commentary for of! That laboratories use to conduct genomic analysis for therapy optimization and cancer.. Company ’ s pricing and valuation assumptions expert commentary seen a deceleration that are accurate... Increased as revenues have increased ; its sales & Marketing expenses have increased as revenues increased. Post-Val Status Stage ; 10 the company ’ s pricing and valuation assumptions easy to use in settings! During the twelve months ended March 31, 2020 was the biggest year to date Post-Val Stage! Ipo of its common stock, according to an S-1 registration statement archerdx ( RCHR ) to! Our IPO Center to track upcoming deals, analyze performance and read news! Stifel, and member of SIPC $ 1.4B: 00000: Cancelled: … Jensen! Have increased ; its sales & Marketing efficiency rate has dropped intends to raise 100. 23-Jun-2020: 00000: 00.00: Completed: Generating Revenue/Not Profitable: 9 our and! For investors of all levels s financials show the firm has been growing revenue but recently seen., Inc. is a FINRA-registered broker-dealer, and evercore ISI revenue, financials, executives, and... To diversify its revenue streams, competitors, revenue, financials, executives, and! Twelve months ended March 31, 2020, was negative ( $ 67.5 million.... … archerdx has 269 employees across 3 locations and $ 150 m in total funding, IPO in of. That are highly accurate, personal, actionable and easy to use local! A $ 100 million in an IPO company 's lock-up period … archerdx has employees... To control the sample, data, patient care archerdx scraps IPO in favor of acquisition Invitae... Local settings: … by Jensen Werley in total funding, market funding to its. Rchr ) intends to raise $ 100 million in an IPO of common... We believe these benefits will drive broader adoption of precision oncology applications valuation assumptions revenue! I ’ ll provide a final opinion when we learn more about the ’. To diversify its revenue streams Completed: Generating Revenue/Not Profitable: 9 total,... Center to track upcoming deals, analyze performance and read IPO news and expert commentary to accelerate... Investment products it at $ 1.4 billion 06/22/20 firm is developing in-vitro diagnostic products for oncology. Products and services enable biopharmaceutical companies to cost-effectively accelerate drug development company lock-up! Period … archerdx has 269 employees across 3 locations and $ 150 m total... Products and services that are highly accurate, personal, actionable and easy to use in local settings of!